Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

Company Overview

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation. The company has also received orphan drug and Fast Track designations for lenabasum in systemic sclerosis and dermatomyositis, underscoring regulatory recognition of its potential to address conditions with limited treatment options. Corbus continues to explore additional indications for its pipeline operations, seeking partnerships and collaborations to support late-stage development and eventual commercialization.

Founded in 2006 and headquartered in Norwood, Massachusetts, Corbus Pharmaceuticals primarily serves patients in North America and Europe through its clinical trial network. Under the leadership of President and Chief Executive Officer Kenneth T. Leonard and Chief Financial Officer Robert J. Conway, the company remains focused on advancing innovative therapies for complex inflammatory diseases and positioning itself as a leader in resolution pharmacology.

Key Stats

• Today's Range: $9.18 to $9.84
• 50-Day Range: $7.38 to $9.74
• 52-Week Range: $7.12 to $20.56
• Volume: 157,974 shs
• Average Volume: 326,954 shs
• Market Capitalization: $180.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.25
• Consensus Rating: Moderate Buy

Corbus Pharmaceuticals Stock Analysis - MarketRank™

Corbus Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 282nd out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Corbus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

Corbus Pharmaceuticals has a consensus price target of $42.25, representing about 333.8% upside from its current price of $9.74.

Amount of Analyst Coverage

Corbus Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($4.87) to ($6.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Corbus Pharmaceuticals is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Corbus Pharmaceuticals is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Corbus Pharmaceuticals has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.72% of the float of Corbus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Corbus Pharmaceuticals has recently increased by 7.77%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Corbus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Corbus Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.21

News Sentiment

Corbus Pharmaceuticals has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Corbus Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for CRBP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

2 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $28,132.00 in company stock, which represents 0.0156% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Corbus Pharmaceuticals insiders have bought 38.50% more of their company's stock than they have sold. Specifically, they have bought $101,205.00 in company stock and sold $73,073.00 in company stock.

Percentage Held by Insiders

3.50% of the stock of Corbus Pharmaceuticals is held by insiders.

Percentage Held by Institutions

64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Today: 8/06/2026
• Last Earnings: 8/06/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CRBP
• CIK: 1595097
• Web: www.corbuspharma.com
• Phone: (617) 963-0100
• Fax: 617-663-6085
• Employees: 40
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Corbus Pharmaceuticals: $42.25
• High Price Target: $53.00
• Low Price Target: $30.00
• Potential Upside/Downside: +333.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$78.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.89%
• Return on Assets: -61.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.92
• Quick Ratio: 7.92

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.40 per share
• Price / Book: 1.16

Miscellaneous

• Outstanding Shares: 18,530,000
• Free Float: 17,880,000
• Market Cap: $180.48 million
• Optionable: Optionable
• Beta: 2.59